Form 4 Tracker
Dianthus Therapeutics, Inc. /DE/
DNTH

32 insider filings · Latest: Sep 17, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Sep 17, 2026Sep 18 8:36 PMEdward CarrCHIEF ACCOUNTING OFFICER
Sale
20,000$101.38$2.0M0(D)

View →

Sep 17, 2026Sep 17 8:28 PMEDWARD CARR
Proposed Sale
20,000$102.49$2.0M—

View →

Sep 1, 2026Sep 3 8:30 PMSimrat RandhawaEVP, Head of R&D
Sale
23,124$106.41$2.5M4,000(D)

View →

Sep 1, 2026Sep 1 8:49 PMSIMRAT RANDHAWA
Proposed Sale
23,124$105.61$2.4M—

View →

Aug 19, 2026Aug 19 10:02 PMSimon ReadDirector
Sale
2,778$117.55$326.6K0(D)

View →

Aug 10, 2026Aug 11 9:15 PMAnne McgeorgeDirector
Sale
7,750$109.01$844.8K0(D)

View →

Aug 10, 2026Aug 11 9:10 PMSimon ReadDirector
Sale
2,777$109.55$304.2K0(D)

View →

Aug 10, 2026Aug 11 9:08 PMAdam M VenessSVP, General Counsel and Sec.
Sale
16,167$110.38$1.8M0(D)

View →

Aug 7, 2026Aug 11 9:08 PMAdam M VenessSVP, General Counsel and Sec.
Sale
3,833$110.70$424.3K0(D)

View →

Aug 10, 2026Aug 10 8:50 PMADAM VENESS
Proposed Sale
16,167$108.92$1.8M—

View →

Aug 10, 2026Aug 10 8:34 PMRead Simon
Proposed Sale
5,550$112.50$624.4K—

View →

Aug 10, 2026Aug 10 8:33 PMANNE M MCGEORGE
Proposed Sale
7,750$108.92$844.1K—

View →

Aug 7, 2026Aug 7 10:30 PMMarino GarciaDirector, CEO AND PRESIDENT
Sale
166,000$108.11$17.9M65,292(D)

View →

Aug 7, 2026Aug 7 8:38 PMMARINO GARCIA
Proposed Sale
40,000$109.92$4.4M—

View →

Aug 7, 2026Aug 7 8:37 PMADAM VENESS
Proposed Sale
3,833$109.92$421.3K—

View →

Aug 7, 2026Aug 7 8:18 PMMARINO GARCIA
Proposed Sale
126,000$108.09$13.6M—

View →

Jul 9, 2026Jul 13 9:00 PMRyan SavitzEVP, CFO & CBO
Sale
31,249$101.03$3.2M0(D)

View →

Jul 9, 2026Jul 9 8:26 PMRYAN SAVITZ
Proposed Sale
31,249$98.07$3.1M—

View →

Jun 17, 2026Jun 18 8:30 PMAdam M VenessSVP, General Counsel and Sec.
Sale
30,000$80.80$2.4M0(D)

View →

Jun 17, 2026Jun 17 8:33 PMADAM M VENESS
Proposed Sale
30,000$78.88$2.4M—

View →

Page 1 of 2

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Apr 9, 2026Apr 10 8:52 PMRyan SavitzEVP, CFO & CBO
Option Exercise
8,224$17.8871,776(D)

View →

Mar 31, 2026Apr 1 9:26 PMRyan SavitzEVP, CFO & CBO
Option Exercise
114,367$17.8880,000(D)

View →

Mar 31, 2026Apr 1 9:26 PMPaula SoteropoulosDirector
Option Exercise
599$8.44599(D)

View →

Mar 24, 2026Mar 26 10:00 PMPaula SoteropoulosDirector
Option Exercise
27,594$8.441,198(D)

View →

Mar 16, 2026Mar 17 9:22 PMMarino GarciaDirector, CEO AND PRESIDENT
Option Exercise
65,292$17.88269,408(D)

View →

Mar 12, 2026Mar 14 12:30 AMMarino GarciaDirector, CEO AND PRESIDENT
Option Exercise
122,918$6.7059,741(D)

View →

Mar 12, 2026Mar 14 12:30 AMEdward CarrCHIEF ACCOUNTING OFFICER
Option Exercise
43,682$22.0750,000(D)

View →

Mar 12, 2026Mar 14 12:30 AMSimrat RandhawaEVP, Head of R&D
Option Exercise
33,830$22.07106,250(D)

View →

Feb 3, 2026Feb 4 10:42 PMEdward CarrCHIEF ACCOUNTING OFFICER
Grant/Award
55,000$52.4655,000(D)

View →

Feb 3, 2026Feb 4 10:41 PMAdam M VenessSVP, General Counsel and Sec.
Grant/Award
100,000$52.46100,000(D)

View →

Feb 3, 2026Feb 4 10:40 PMSimrat RandhawaEVP, Head of R&D
Grant/Award
150,000$52.46150,000(D)

View →

Feb 3, 2026Feb 4 10:40 PMRyan SavitzEVP, CFO & CBO
Grant/Award
150,000$52.46150,000(D)

View →

Feb 3, 2026Feb 4 10:39 PMMarino GarciaDirector, CEO AND PRESIDENT
Grant/Award
355,000$52.46355,000(D)

View →

← Previous

Page 2 of 2